Research Program Members
Professor
612-624-0123
afrinl@umn.edu
Chronic myeloproliferative neoplasms, especially the mast cell activation diseases and in particular the newly recognized mast cell activation syndrome; expertise in medical informatics.
Associate Professor
612-624-0123
arora005@umn.edu
Development of novel strategies for preventing chronic GVHD and identification of risk factors
Associate Professor
612-624-0123
bach0173@umn.edu
Immune-based therapies for lymphoma and other related malignancies
Assistant Professor
612-624-6982
nbejanya@umn.edu
Development of novel clinical trials for reducing the early complications of allogeneic HCT and limiting myeloid leukemia recurrence.
Regents Professor
612-626-2734
blaza001@umn.edu
Regulation of the immune response after allogeneic HCT using murine model systems, development of immune-based therapies (e.g., use of Treg cells to modulate engraftment and GVHCO, and development of stem cell-based therapies for tissue repair after chemoradiotherapy.
Associate Professor
612-624-0123
bruns072@umn.edu
The application of unrelated cord blood transplantation in adults; clinical trials evaluating a) complement fragment 3a (C3a) as a method for enhancing the home of UCB HSC to the hematopoietic niche, b) UCB-derived Treg as a strategy to reduce or prevent acute GVHD, and c) CTN trials exporting the use of the double UCB platform in the context of non-myeloablative conditioning
Assistant Professor
612-626-8284
cich0040@umn.edu
Adaptive natural killer (NK) cell responses to viral infection and how these responses can be translated into novel therapies for hematopoietic stem cell transplantation recipients; NK cell signaling and primary immunodeficiences that impact NK cell function
Associate Professor
612-625-8474
cool0023@umn.edu
Development of NK cell-based immunotherapies to treat leukemia and breast cancer
Assistant Professor
612-626-6019
eckf0002@umn.edu
Understanding the role of RAS signaling pathways in acute myeloid leukemia (AML) to provide a foundation for the rational development of novel targeted therapies for human AML.
Assistant Professor
612-625-8942
mfelices@umn.edu
Natural killer (NK) cell biology, with a particular interest on NK cell education, signaling, and metabolism. The ultimate goal is to manipulate these pathways to enhance NK cell survival, expansion and anti-tumor function.
Associate Professor
612-626-0665
gelle005@umn.edu
Ovarian cancer and the treatment of uterine sarcomas, identification early in the course of treatment of the alterations in biomarker and gene profiles that will predict response to chemotherapy
Professor
612-467-4135
gupta013@umn.edu
The role of proteoglycans in hematopoiesis and interactions between normal and leukemic stem cells with the microenvironment
Assistant Professor
612-625-1430
hippe002@umn.edu
Translational development of nTreg and iTreg from adult peripheral blood and UCB, T progenitors from UCB and large scael manufacture of UCB CD19 T-CAR as a strategy for eradicating residual CD19 malignancies
Assistant Professor
612-301-1095
sgholtan@umn.edu
Graft versus host disease; Immune reconstitution post-hematopoietic cell transplant; immune-based cancer therapies; melanoma
.jpg)
Professor
612-624-6118
jacob117@umn.edu
Pharmacokinetics/pharacodynamics of chemotherapeutic and immunosuppressive agents for prevention of therapy-related complications
.jpg)
Assistant Professor
612-624-5430
joh02745@umn.edu
Effects of chemotherapy in cancer patients and how responses differ depending on genetics and other factors
Associate Professor
612-624-0498
kikyo001@umn.edu
Mechanisms of nuclear reprogramming and how differentiated somatic nuclei are de-differentiated in egg cytoplasm and re-differentiated during subsequent embryogenesis
Associate Professor
612-625-2173
kyba@umn.edu
The differentiation of embryonic and induced pluirpotential stem cells into muscle and hematopoietic stem cells
Professor
612-624-9963
chap@umn.edu
Data-driven and include epidemiological methods, cross-over designs, survival analysis, ordered alternatives, ROC curves, and methods for the analysis of in vitro experiments—especially chemo-combination therapy
Associate Professor
612-625-4185
lundx072@umn.edu
Understanding the pathophysiological processes underlying metabolic storages diseases (ALD, MLD, MPSI, ETC) and improving the outcomes for metabolic storage disease hematopoietic cell transplantation using the zebrafish model; hematopoietic cell engraftment process during bone marrow transplantation and improving the efficiency and time to engraftment
Professor
612-626-5768
macmi002@umn.edu
Prevention and treatment of acute GVHD; clincial trials using iTreg for prevention of acute GVHD in recipients of HLA-matched peripheral blood stem cells
Assistant Professor
612-624-0123
bmcclune@umn.edu
Clinical trials in hematologic malignancy using stem cell transplantation
Professor Emeritus
612-626-3272
mccul001@umn.edu
Transfusion medicine as it relates to cancer and HCT patients (e.g. leukocyte infusions in sepsis, platelet alloimmunization); development of novel therapies
Professor
612-624-0123
mcgla001@umn.edu
Treatment of malignant and nonmalignant hematologic disorders including aplastic anemia, leukemia, lymphoma, multiple myeloma, myelodysplasia, and blood and marrow transplantation; experimental therapy for malignant and non-malignant hematologic disorders including stem cell transplantation, immunotherapy, and gene transfer
Professor
612-624-5736
mcken020@umn.edu
Development of novel cellular therapies
Assistant Professor
612-626-5768
mill4991@umn.edu
Development of novel clinical HCT trials in patients with metabolic disease; understanding the impact of high resolution HLA matching of UCB
Assistant Professor
612-625-8327
osbor026@umn.edu
Biology of homologous recombination as a strategy for gene transfer into HSC of patients with various genetic diseases, including Fanconi anemia
Professor
612-626-2950
panos001@umn.edu
The pathophysiology of acute lung injury in the setting of allogeneic HCT and GVHD and leads studies in pulmonary regenerative medicine
Professor
612-625-4984
perli032@umn.edu
Mechanisms underlying stem cell regulation and its relevance for tissue regneration and development of leukemia
Professor
612-624-0123
slung001@umn.edu
Inflammatory mediators of coagulation and vascular integrity with direct relevance to tumor vascularity and thrombosis in patients with cancer
Assistant Professor
612-626-8094
smith719@umn.edu
Early and late effects of HCT, with a focus on venoocclusive disease of the liver and infertility
Assistant Professor
612-625-4193
stef0030@umn.edu
Thymic epithelial cell protection and expansion of T progenitors (Tprog) extrapolated from the murine model
Distinguished McKnight Professor
612-625-2912
tolar003@umn.edu
Development of non-hematopoietic stem cells for use in tissue repair particularly precancerous genetic diseases like epidermolysis bullosa, dykeratosis congentia and Fanconi anemia.
Associate Professor
612-624-0123
custun@umn.edu
Clinical trials for acute myeloid leukemia and related myeloid malignancies
Professor
612-624-0123
verce001@umn.edu
Inflammation, oxidative stress and endothelial integrity
Professor
612-626-2961
wagne002@umn.edu
Development of UCB as a source of hematopoietic and non-hematopoietic stem cells for treatment of malignancy; pathophysiology of Fanconi anemia and Epidermolysis bullosa predisposition to malignancy
Associate Professor
612-624-0123
ewarlick@umn.edu
The development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases
Professor
612-626-5501
weige007@umn.edu
Testing new pharmacological and cellular therapeutic agents in preclinical mouse models and phase 1 testing in children
Professor
612-624-3101
weisd001@umn.edu
Application of transplant therapy for acute leukemia as well as prevention and treatment of acute and chronic GVHD and late effects of HCT
